Amylyx Pharmaceuticals, Inc.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
The lawsuit claims that during the relevant period, the Defendants made significantly untrue and/or misleading statements and/or did not reveal that: (i) they had exaggerated the market potential of RELYVRIO, a treatment for ALS in adults in the U.S., which combines sodium phenylbutyrate and taurursodiol as a dual UPRBax apoptosis inhibitor; (ii) there was a trend of patients stopping their treatment with RELYVRIO after six months; (iii) the number of new patients beginning treatment with RELYVRIO was on the decline; (iv) therefore, the reported prescription rates for RELYVRIO were overly inflated; (v) the defendants tried to obscure these adverse trends from investors and the market by preventing analysts from accessing RELYVRIO’s prescription data; and (vi) consequently, the public statements made by the defendants were significantly incorrect and misleading throughout the relevant times.
